Silexion Therapeutics (SLXN) Competitors $1.17 -0.01 (-0.85%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.18 +0.02 (+1.28%) As of 03/28/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. FGEN, ALXO, CVKD, OSTX, IRD, TPST, ESLA, RVPH, XCUR, and NRXPShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include FibroGen (FGEN), ALX Oncology (ALXO), Cadrenal Therapeutics (CVKD), OS Therapies (OSTX), Opus Genetics (IRD), Tempest Therapeutics (TPST), Estrella Immunopharma (ESLA), Reviva Pharmaceuticals (RVPH), Exicure (XCUR), and NRx Pharmaceuticals (NRXP). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. FibroGen ALX Oncology Cadrenal Therapeutics OS Therapies Opus Genetics Tempest Therapeutics Estrella Immunopharma Reviva Pharmaceuticals Exicure NRx Pharmaceuticals Silexion Therapeutics (NASDAQ:SLXN) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment. Which has better earnings and valuation, SLXN or FGEN? Silexion Therapeutics has higher earnings, but lower revenue than FibroGen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A$260KN/AN/AFibroGen$29.62M1.07-$284.23M-$0.48-0.65 Does the media favor SLXN or FGEN? In the previous week, FibroGen had 5 more articles in the media than Silexion Therapeutics. MarketBeat recorded 8 mentions for FibroGen and 3 mentions for Silexion Therapeutics. FibroGen's average media sentiment score of 1.10 beat Silexion Therapeutics' score of 0.31 indicating that FibroGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral FibroGen 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, SLXN or FGEN? Silexion Therapeutics has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Is SLXN or FGEN more profitable? Silexion Therapeutics has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -249.43% FibroGen -67.66%N/A -36.17% Does the MarketBeat Community prefer SLXN or FGEN? FibroGen received 344 more outperform votes than Silexion Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Silexion Therapeutics an outperform vote while only 59.55% of users gave FibroGen an outperform vote. CompanyUnderperformOutperformSilexion TherapeuticsOutperform Votes2100.00% Underperform VotesNo VotesFibroGenOutperform Votes34659.55% Underperform Votes23540.45% Do insiders & institutionals have more ownership in SLXN or FGEN? 10.9% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 33.0% of Silexion Therapeutics shares are owned by insiders. Comparatively, 2.0% of FibroGen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts prefer SLXN or FGEN? Silexion Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 327.35%. FibroGen has a consensus target price of $10.00, indicating a potential upside of 3,086.74%. Given FibroGen's higher possible upside, analysts plainly believe FibroGen is more favorable than Silexion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryFibroGen beats Silexion Therapeutics on 8 of the 13 factors compared between the two stocks. Remove Ads Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.85M$3.03B$5.63B$7.84BDividend YieldN/A1.55%5.33%4.01%P/E RatioN/A30.4523.6018.74Price / SalesN/A431.82388.2390.77Price / Cash1.46168.6838.1734.64Price / Book-0.183.926.894.23Net Income$260,000.00-$71.95M$3.20B$247.47M7 Day Performance2.63%-5.68%-3.06%-2.29%1 Month Performance9.35%-12.09%1.52%-5.81%1 Year PerformanceN/A-27.90%9.37%-0.96% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$1.17-0.8%$5.00+327.4%N/A$9.85MN/A0.00N/AFGENFibroGen4.5498 of 5 stars$0.37+17.1%$10.00+2,610.0%-86.6%$37.24M$29.62M-0.30570Analyst ForecastPositive NewsGap UpALXOALX Oncology3.9606 of 5 stars$0.69-2.4%$4.14+499.7%-94.1%$36.85MN/A-0.2340Positive NewsCVKDCadrenal Therapeutics2.5644 of 5 stars$19.50+0.7%$32.00+64.1%N/A$36.66MN/A-2.924Short Interest ↑OSTXOS Therapies2.1899 of 5 stars$1.68-2.9%$17.50+941.7%N/A$36.57MN/A0.00N/AIRDOpus Genetics2.5219 of 5 stars$1.15-8.7%$8.00+595.7%N/A$36.30M$8.38M-1.0614Upcoming EarningsHigh Trading VolumeTPSTTempest Therapeutics2.7361 of 5 stars$0.83+0.4%$26.00+3,051.5%-80.3%$36.01MN/A-0.5420Earnings ReportUpcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionGap DownESLAEstrella Immunopharma2.4437 of 5 stars$0.99-2.0%$16.00+1,516.5%-23.5%$35.81MN/A-3.81N/APositive NewsRVPHReviva Pharmaceuticals4.1753 of 5 stars$1.07+2.9%$11.40+965.4%-73.3%$35.78MN/A-0.965Short Interest ↓News CoverageXCURExicure1.2466 of 5 stars$13.57-3.4%N/A+2,225.9%$35.36M$500,000.00-6.5650Short Interest ↑Gap DownNRXPNRx Pharmaceuticals2.5952 of 5 stars$2.07-0.5%$31.67+1,429.8%-95.7%$35.02MN/A-0.972 Remove Ads Related Companies and Tools Related Companies FibroGen Alternatives ALX Oncology Alternatives Cadrenal Therapeutics Alternatives OS Therapies Alternatives Opus Genetics Alternatives Tempest Therapeutics Alternatives Estrella Immunopharma Alternatives Reviva Pharmaceuticals Alternatives Exicure Alternatives NRx Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLXN Stock Free SLXN Stock Alerts